Acta Radiol

1. ELSHEWY NE, Ramadan AA, Sameh WM, Eid ME, et al
   Does volumetric measurement of ADC values achieve higher diagnostic performance in bladder cancer MRI?
   Acta Radiol. 2024 Apr 9:2841851241241055. doi: 10.1177/02841851241241055.
   

   >> Share

   
   

   
   Adv Anat Pathol

2. AKBULUT D, Al-Ahmadie H
   Updates on Urinary Bladder Tumors With Neuroendocrine Features.
   Adv Anat Pathol. 2024;31:169-177.
   

   >> Share

   
   

   
   Adv Radiat Oncol

3. AGRAWAL S, Gupta A, Kapoor V, Rahul R, et al
   Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers.
   Adv Radiat Oncol. 2024;9:101468.
   

   >> Share

   
   

   
   Aging (Albany NY)

4. DENG H, Cheng F, Cheng S
   Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
   Aging (Albany NY). 2024;16:5751-5771.
   

   >> Share

   
   

   
   Am J Cancer Res

5. WEN X, Hou J, Chu Y, Liao G, et al
   Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.
   Am J Cancer Res. 2024;14:959-978.
   

   >> Share

   
   

   
   Ann Oncol

6. LORIOT Y, Petrylak DP, Rezazadeh Kalebasty A, Flechon A, et al
   TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
   Ann Oncol. 2024;35:392-401.
   

   >> Share

   
   

   
   Ann Surg Oncol

7. URABE F, Tsuzuki S, Kimura T
   Letter to the Editor for the Article "Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma".
   Ann Surg Oncol. 2024;31:3563-3564.
   

   >> Share

   
   
8. MILOJEVIC B
   Reply to: Letter to the Editor for the Article "Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma," by Urabe, Fumihik et al.
   Ann Surg Oncol. 2024;31:3565-3566.
   

   >> Share

   
   
9. SLUSARCZYK A
   ASO Author Reflections: Changes in the Urinary Microbiome After Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
   Ann Surg Oncol. 2024 Apr 11. doi: 10.1245/s10434-024-15248.
   

   >> Share

   
   

   
   Arch Esp Urol

10. ZHANG X, Liu Q, Yi K, Liu S, et al
    The Prognostic Value of the Combination of the Prognostic Nutritional Index and the Lymphocyte:Monocyte Ratio for the Prediction of Patients with Muscle-Invasive Bladder Cancer.
    Arch Esp Urol. 2024;77:164-172.
    

    >> Share

    
    
11. REN H, Wang K, Liu C
    Analysis of the Clinicopathological Characteristics and Prognosis of Patients with Nonurothelial Bladder Cancer.
    Arch Esp Urol. 2024;77:148-157.
    

    >> Share

    
    

    
    Biochem Pharmacol

12. SANG J, Liu CK, Liu J, Luo GC, et al
    Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.
    Biochem Pharmacol. 2024;223:116194.
    

    >> Share

    
    

    
    Cancer Cytopathol

13. MIYAI K, Nakayama M, Minabe S, Ogata S, et al
    Implementation of The Paris System for Reporting Urine Cytology improves diagnostic accuracy of selective upper urinary tract cytology.
    Cancer Cytopathol. 2024;132:242-249.
    

    >> Share

    
    

    
    Cancer Imaging

14. ZHANG X, Wang Y, Wang Y, Zhang J, et al
    MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy.
    Cancer Imaging. 2024;24:49.
    

    >> Share

    
    

    
    Cancer Lett

15. LIU K, Chen H, Li Y, Wang B, et al
    Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapetuics.
    Cancer Lett. 2024 Apr 7:216867. doi: 10.1016/j.canlet.2024.216867.
    

    >> Share

    
    

    
    Cancer Pathog Ther

16. MAROOF H, Paramore L, Ali A
    Theories behind Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer and update on current management.
    Cancer Pathog Ther. 2023;2:74-80.
    

    >> Share

    
    

    
    Cell Signal

17. LYU F, Huang S, Yan Z, He Q, et al
    CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
    Cell Signal. 2024 Apr 5:111164. doi: 10.1016/j.cellsig.2024.111164.
    

    >> Share

    
    

    
    Cells

18. ALHOZEEL B, Pandey SK, Shteinfer-Kuzmine A, Santhanam M, et al
    Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer.
    Cells. 2024;13:627.
    

    >> Share

    
    

    
    Chem Commun (Camb)

19. WANG J, Guo F, Zhang J, Chao J, et al
    Potential-resolved electrochemiluminescence for simultaneous determination of multiplex bladder cancer markers.
    Chem Commun (Camb). 2024 Apr 8. doi: 10.1039/d4cc00996.
    

    >> Share

    
    

    
    Crit Rev Oncol Hematol

20. MONTEIRO FSM, Soares A, Mollica V, Leite CA, et al
    Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
    Crit Rev Oncol Hematol. 2024;196:104321.
    

    >> Share

    
    
21. OTIS SU, Banna GL, Maniam A
    The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma - A review of the literature.
    Crit Rev Oncol Hematol. 2024;196:104314.
    

    >> Share

    
    

    
    Curr Opin Urol

22. ENGLINGER B
    Molecular research in bladder cancer.
    Curr Opin Urol. 2024 Apr 12. doi: 10.1097/MOU.0000000000001181.
    

    >> Share

    
    
23. NOSSING C, Herek P, Shariat SF, Berger W, et al
    Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
    Curr Opin Urol. 2024 Apr 11. doi: 10.1097/MOU.0000000000001177.
    

    >> Share

    
    
24. ABUFARAJ M, Al Karmi J, Bdeir A
    Is there a role for metastasis-directed therapy in bladder cancer?
    Curr Opin Urol. 2024 Apr 5. doi: 10.1097/MOU.0000000000001174.
    

    >> Share

    
    

    
    Discov Oncol

25. TANG L, Xu H, Wu T, Wu W, et al
    Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review.
    Discov Oncol. 2024;15:111.
    

    >> Share

    
    

    
    Environ Toxicol

26. ZENG X, Su H, Liu Z, Wang Y, et al
    Integrative analysis of the bladder cancer from a cell cycle NCAM1 perspective at both single cell and bulk resolution.
    Environ Toxicol. 2024 Apr 6. doi: 10.1002/tox.24260.
    

    >> Share

    
    

    
    Eur Urol

27. BABJUK M
    Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Apr 9:S0302-2838(24)02262-0. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Eur Urol Focus

28. VOGL UM, Testi I, De Santis M
    Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
    Eur Urol Focus. 2024 Apr 5:S2405-4569(24)00049-X. doi: 10.1016/j.euf.2024.
    

    >> Share

    
    

    
    Eur Urol Open Sci

29. P VAN VALENBERG FJ, van der Heijden AG, Cutie CJ, Bhanvadia S, et al
    The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.
    Eur Urol Open Sci. 2024;62:8-15.
    

    >> Share

    
    

    
    Expert Rev Anticancer Ther

30. HE S, Xu J, Chen M, Li J, et al
    A meta-analysis of UCA1 accuracy in the detection of bladder cancer.
    Expert Rev Anticancer Ther. 2024 Apr 12. doi: 10.1080/14737140.2024.2342528.
    

    >> Share

    
    

    
    Front Immunol

31. HAN Z, Ai J
    Editorial: Biomarkers and immunotherapy for genitourinary tumors.
    Front Immunol. 2024;15:1394170.
    

    >> Share

    
    

    
    Int J Urol

32. SAKURA Y, Yamashita R, Notsu A, Usui K, et al
    Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
    Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
    

    >> Share

    
    

    
    Int Urol Nephrol

33. ZHU W, Wu L, Xie W, Zhang G, et al
    Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis.
    Int Urol Nephrol. 2024;56:1525-1535.
    

    >> Share

    
    

    
    Iran J Immunol

34. ARIAFAR A, Kohansal E, Mousania A, Faghih Z, et al
    Natural Killer Cell Subsets in Tumor Draining Lymph Nodes of Patients with Bladder Cancer and Their Clinical Implications.
    Iran J Immunol. 2024;21.
    

    >> Share

    
    

    
    J Cancer Res Clin Oncol

35. HIRASAWA Y, Adachi T, Hashimoto T, Fukuokaya W, et al
    Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
    J Cancer Res Clin Oncol. 2024;150:182.
    

    >> Share

    
    
36. HONG S, Lee JH, Heo JY, Suh KJ, et al
    Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
    J Cancer Res Clin Oncol. 2024;150:186.
    

    >> Share

    
    

    
    J Cutan Pathol

37. CHO WC, Saade R, Nagarajan P, Aung PP, et al
    Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
    J Cutan Pathol. 2024 Jan 10. doi: 10.1111/cup.14579.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

38. TOSI A, Parisatto B, Gaffo E, Bortoluzzi S, et al
    A paclitaxel-hyaluronan conjugate (ONCOFID-P-B) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.
    J Exp Clin Cancer Res. 2024;43:109.
    

    >> Share

    
    

    
    J Immunother Cancer

39. WANG B, Zhou B, Chen J, Sun X, et al
    Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.
    J Immunother Cancer. 2024;12:e007808.
    

    >> Share

    
    

    
    J Natl Cancer Inst

40. GUPTA S, Andreev-Drakhlin A, Fajardo O, Fasso M, et al
    Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
    J Natl Cancer Inst. 2024;116:547-554.
    

    >> Share

    
    

    
    J Pak Med Assoc

41. NUSRAT NB, Rehman AU, Zafar N, Muhammad S, et al
    Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
    J Pak Med Assoc. 2024;74:513-518.
    

    >> Share

    
    
42. HASSAN M, Quereshi AH
    Paraganglioma of the urinary bladder: A case report.
    J Pak Med Assoc. 2024;74:570-572.
    

    >> Share

    
    

    
    J Pediatr Surg

43. CEYHAN E, Mammadov E, Onder SC, Dogan HS, et al
    Fish: A Promising Screening Tool for Malignancy After Augmentation Cystoplasty?
    J Pediatr Surg. 2024;59:725-730.
    

    >> Share

    
    

    
    J Physiol Pharmacol

44. SZYMANSKA B, Debowski J, Malkiewicz B, Piwowar A, et al
    Assessment of interleukin 17A and 23 in the course of bladder cancer and selected benign urological diseases.
    J Physiol Pharmacol. 2024;75.
    

    >> Share

    
    

    
    J Surg Oncol

45. PULLEN L, Costa PF, Darr C, Hess J, et al
    Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience.
    J Surg Oncol. 2024 Apr 7. doi: 10.1002/jso.27618.
    

    >> Share

    
    

    
    J Urol

46. KAY H, Silver SN, Smith AB, Basak R, et al
    Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study.
    J Urol. 2024 Apr 11:101097JU0000000000003964. doi: 10.1097/JU.0000000000003964.
    

    >> Share

    
    

    
    Medicine (Baltimore)

47. ZHANG M, Guo S, Gan S, Xu Q, et al
    "Internet Plus" continuous nursing for patients with advanced bladder cancer: A retrospective observational study.
    Medicine (Baltimore). 2024;103:e37822.
    

    >> Share

    
    

    
    Mol Med Rep

48. DU Y, Zhang X, Zhang H, Chen Y, et al
    [Retracted] Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR?145?5p/TOP2A axis.
    Mol Med Rep. 2024;29:94.
    

    >> Share

    
    

    
    Mol Nutr Food Res

49. WANG Z, Kwan ML, Haque R, Singh PK, et al
    Modifying Effects of Genetic Variations on the Association Between Dietary Isothiocyanate Exposure and Non-muscle Invasive Bladder Cancer Prognosis in the Be-Well Study.
    Mol Nutr Food Res. 2024 Apr 6:e2400087. doi: 10.1002/mnfr.202400087.
    

    >> Share

    
    

    
    Nat Rev Urol

50. PANEBIANCO V, Briganti A, Boellaard TN, Catto J, et al
    Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System.
    Nat Rev Urol. 2024;21:243-251.
    

    >> Share

    
    

    
    Res Rep Urol

51. AVILEZ ND, Capibaribe DM, Reis LO
    Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Res Rep Urol. 2024;16:89-113.
    

    >> Share

    
    

    
    Rev Esp Patol

52. IGLESIAS DE USSEL GALARRETA I, Queipo Gutierrez FJ
    Stromal osseous metaplasia in urothelial carcinoma of the bladder: An unusual and challenging feature. A case report.
    Rev Esp Patol. 2024;57:116-119.
    

    >> Share

    
    

    
    Sci Rep

53. KIM JS, Lee J, Nguyen TT, Choi SY, et al
    Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
    Sci Rep. 2024;14:8440.
    

    >> Share

    
    
54. SU SW, Chen X, Wang G, Li P, et al
    A study on the significance of serine hydroxymethyl transferase expression and its role in bladder cancer.
    Sci Rep. 2024;14:8324.
    

    >> Share

    
    
55. CARROLL RA, Rice ES, Murphy WJ, Lyons LA, et al
    A chromosome-scale fishing cat reference genome for the evaluation of potential germline risk variants.
    Sci Rep. 2024;14:8073.
    

    >> Share

    
    
56. ZHANG C, Xu X, Wang T, Lu Y, et al
    Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
    Sci Rep. 2024;14:7941.
    

    >> Share

    
    

    
    Transl Androl Urol

57. PIJPERS OM, Boormans JL
    Disease progression in Bacillus Calmette Guerin unresponsive non-muscle invasive bladder cancer patients with carcinoma in situ, participating in clinical trials on bladder-sparing treatment.
    Transl Androl Urol. 2024;13:479-482.
    

    >> Share

    
    
58. KIM S, St-Laurent MP, Black P
    Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.
    Transl Androl Urol. 2024;13:458-462.
    

    >> Share

    
    

    
    Urol J

59. XU C, Xiong B
    Prognostic Nomograms for Patients with Primary Sarcomatoid Carcinoma of The Urinary Bladder: Based on The SEER Database.
    Urol J. 2024;21:87-97.
    

    >> Share

    
    
60. TANG F, Wang X, Liu T, Wang H, et al
    Multiple Fluorescences in Situ Hybridization Status in Excreted Urine Improve Diagnostic Efficacy for Upper Urinary Tract Urothelial Carcinomas.
    Urol J. 2024;21:107-113.
    

    >> Share

    
    

    
    Urol Oncol

61. KURAL S, Jain G, Agarwal S, Das P, et al
    Urinary extracellular vesicles-encapsulated miRNA signatures: A new paradigm for urinary bladder cancer diagnosis and classification.
    Urol Oncol. 2024 Apr 8:S1078-1439(24)00361-2. doi: 10.1016/j.urolonc.2024.
    

    >> Share

    
    

    
    World J Urol

62. SONG B, Kim JK, Lee H, Lee S, et al
    Evaluation of histological variants of upper tract urothelial carcinoma as prognostic factor after radical nephroureterectomy.
    World J Urol. 2024;42:225.
    

    >> Share

    
    
63. LI C, Lu B, Zhao Q, Lu Q, et al
    Development and validation of a clinical and ultrasound features-based nomogram for preoperative differentiation of renal urothelial carcinoma and central renal cell carcinoma.
    World J Urol. 2024;42:227.
    

    >> Share

    
    
64. HANNA P, Zabell J, Konety B, Warlick C, et al
    Perioperative complications and oncological outcomes of open versus robotic-assisted radical cystectomy: a propensity score-matched study.
    World J Urol. 2024;42:220.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share